These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27861630)

  • 1. Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
    PLoS One; 2016; 11(11):e0167251. PubMed ID: 27861630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
    PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.
    Reuss JE; Kunk PR; Stowman AM; Gru AA; Slingluff CL; Gaughan EM
    J Immunother Cancer; 2016; 4():94. PubMed ID: 28031822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
    Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
    Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
    Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
    Chan PY; Hall P; Hay G; Cohen VML; Szlosarek PW
    Pigment Cell Melanoma Res; 2017 Jan; 30(6):558-562. PubMed ID: 28640512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
    Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
    Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JJ; Kuntz KW; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
    PLoS One; 2017; 12(1):e0170539. PubMed ID: 28085948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.
    Spain L; Larkin J
    Expert Opin Biol Ther; 2016; 16(3):389-96. PubMed ID: 26750801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Identification of microRNAs in Macaca fascicularis (Cynomolgus Monkey) by Homology Search and Experimental Validation by Small RNA-Seq and RT-qPCR Using Kidney Cortex Tissues.
    Veeranagouda Y; Rival P; Prades C; Mariet C; Léonard JF; Gautier JC; Zhou X; Wang J; Li B; Ozoux ML; Boitier E
    PLoS One; 2016; 11(10):e0164317. PubMed ID: 27695060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: The extracellular domain of myelin oligodendrocyte glycoprotein elicits atypical experimental autoimmune encephalomyelitis in rat and macaque species.
    The
    PLoS One; 2015; 10(2):e0117878. PubMed ID: 25658938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
    Koppolu V; Rekha Vasigala VK
    J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Transduction of SIV-Specific TCR Genes into Rhesus Macaque CD8+ T Cells Conveys the Ability to Suppress SIV Replication.
    Barsov EV; Trivett MT; Minang JT; Sun H; Ohlen C; Ott DE
    PLoS One; 2018; 13(3):e0195246. PubMed ID: 29590210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
    Carlino MS; Long GV
    Clin Cancer Res; 2016 Aug; 22(16):3992-8. PubMed ID: 27340279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
    Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
    Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
    Ali AK; Watson DE
    Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy-induced hypothyroidism A report of melanoma treated by ipilimumab and nivolumab.
    Haissagerre M; Prey S; Lauro C; Rousset M; Georges A; Corcuff JB
    Ann Biol Clin (Paris); 2018 Jun; 76(3):326-328. PubMed ID: 29862971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.